Talea Group Valuation
Is U5Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of U5Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: U5Y (€4.25) is trading below our estimate of fair value (€15.62)
Significantly Below Fair Value: U5Y is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for U5Y?
Key metric: As U5Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is U5Y's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | €137.58m |
| Market Cap | €30.70m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | -12.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does U5Y's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
RDC Redcare Pharmacy | 1.3x | 17.6% | €2.9b |
MSH WASGAU Produktions & Handels | 0.09x | n/a | €56.8m |
HAW Hawesko Holding | 0.3x | 3.1% | €209.3m |
DMVF3 d1000 Varejo Farma Participações | 0.2x | n/a | R$354.2m |
U5Y Talea Group | 0.2x | 17.9% | €30.7m |
Price-To-Sales vs Peers: U5Y is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.5x).
Price to Sales Ratio vs Industry
How does U5Y's PS Ratio compare vs other companies in the European Consumer Retailing Industry?
| 10 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: U5Y is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Consumer Retailing industry average (0.3x).
Price to Sales Ratio vs Fair Ratio
What is U5Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 0.2x |
Price-To-Sales vs Fair Ratio: U5Y is expensive based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €4.25 | €10.70 +151.8% | 6.5% | €11.40 | €10.00 | n/a | 2 |
| Nov ’25 | €4.35 | €11.30 +159.8% | 9.1% | €12.50 | €10.00 | n/a | 3 |
| Oct ’25 | €6.20 | €11.25 +81.5% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| Sep ’25 | €6.58 | €11.25 +71.0% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| Aug ’25 | €6.84 | €11.25 +64.5% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| Jul ’25 | €7.12 | €11.25 +58.0% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| Jun ’25 | €5.58 | €11.25 +101.6% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| May ’25 | €5.32 | €11.25 +111.5% | 11.1% | €12.50 | €10.00 | n/a | 2 |
| Apr ’25 | €5.40 | €11.90 +120.4% | 5.0% | €12.50 | €11.30 | n/a | 2 |
| Mar ’25 | €6.46 | €15.15 +134.5% | 9.6% | €16.60 | €13.70 | n/a | 2 |
| Feb ’25 | €7.92 | €15.15 +91.3% | 9.6% | €16.60 | €13.70 | n/a | 2 |
| Jan ’25 | €8.24 | €15.15 +83.9% | 9.6% | €16.60 | €13.70 | n/a | 2 |
| Dec ’24 | €7.72 | €15.15 +96.2% | 9.6% | €16.60 | €13.70 | n/a | 2 |
| Nov ’24 | €8.04 | €15.15 +88.4% | 9.6% | €16.60 | €13.70 | €4.35 | 2 |
| May ’24 | €10.65 | €17.25 +62.0% | 13.0% | €19.50 | €15.00 | €5.32 | 2 |
| Apr ’24 | €10.28 | €17.25 +67.8% | 13.0% | €19.50 | €15.00 | €5.40 | 2 |
| Mar ’24 | €12.54 | €17.00 +35.6% | 5.9% | €18.00 | €16.00 | €6.46 | 2 |
| Feb ’24 | €12.18 | €15.50 +27.3% | 3.2% | €16.00 | €15.00 | €7.92 | 2 |
| Jan ’24 | €10.86 | €15.50 +42.7% | 3.2% | €16.00 | €15.00 | €8.24 | 2 |
| Dec ’23 | €11.52 | €15.50 +34.5% | 3.2% | €16.00 | €15.00 | €7.72 | 2 |
| Nov ’23 | €9.36 | €15.50 +65.6% | 3.2% | €16.00 | €15.00 | €8.04 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.